Skip to content

Dyslipidaemia

Three documents: the ACC/AHA 2026 US guideline, and the ESC/EAS 2019 European guideline with its 2025 focused update. Both now use LDL-C goals.

ACC/AHA 2026

International Current

2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia

Official source

ESC/EAS 2019

International Current

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Official source

ESC/EAS 2025 focused update

International Current

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Official source

Where they agree and differ

ACC/AHA 2026 ESC/EAS 2019 + 2025
Risk tool PREVENT (10-year ASCVD) SCORE2 / SCORE2-OP
Very-high-risk goal <55 mg/dL (very-high-risk ASCVD) <55 mg/dL (1.4 mmol/L) + ≥50% fall
High-risk goal <70 mg/dL <70 mg/dL (1.8 mmol/L) + ≥50% fall
Moderate risk <100 mg/dL <100 mg/dL (2.6 mmol/L)
Lp(a) Once in every adult; high ≥125 nmol/L (≥50 mg/dL) Once in a lifetime; >50 mg/dL is a risk enhancer
Add-on order Ezetimibe → PCSK9 mAb / bempedoic acid / inclisiran Ezetimibe → PCSK9 inhibitor; bempedoic acid if statin-intolerant